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Abstract
Background: Interaction of CD200 with its receptor CD200R has an immunoregulatory role and attenuates various
types of neuroinflammatory diseases.
Methods: Immunofluorescence staining, western blot analysis, and RT-PCR were used to investigate the modulatory
effects of CD200 fusion protein (CD200Fc) on activation of microglia and astrocytes as well as synthesis of
pro- (TNF, IL-1β, IL-6) and anti-inflammatory (IL-4, IL-10) cytokines in the L4–L5 spinal cord segments in relation to
behavioral signs of neuropathic pain after unilateral sterile chronic constriction injury (sCCI) of the sciatic nerve.
Withdrawal thresholds for mechanical hypersensitivity and latencies for thermal hypersensitivity were measured
in hind paws 1 day before operation; 1, 3, and 7 days after sCCI operation; and then 5 and 24 h after intrathecal
application of artificial cerebrospinal fluid or CD200Fc.
Results: Seven days from sCCI operation and 5 h from intrathecal application, CD200Fc reduced mechanical and
thermal hypersensitivity when compared with control animals. Simultaneously, CD200Fc attenuated activation of
glial cells and decreased proinflammatory and increased anti-inflammatory cytokine messenger RNA (mRNA) levels.
Administration of CD200Fc also diminished elevation of CD200 and CD200R proteins as a concomitant reaction of the
modulatory system to increased neuroinflammatory reactions after nerve injury. The anti-inflammatory effect of
CD200Fc dropped at 24 h after intrathecal application.
Conclusions: Intrathecal administration of the CD200R1 agonist CD200Fc induces very rapid suppression of
neuroinflammatory reactions associated with glial activation and neuropathic pain development. This may constitute a
promising and novel therapeutic approach for the treatment of neuropathic pain.
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Background
Peripheral neuropathic pain (PNP), manifesting as
spontaneous pain, arises as a result of many forms of
nerve damage, including traumatic nerve injury, dia-
betic neuropathy, HIV neuropathy, and drug-induced
neuropathy [1, 2]. Among other effects, nerve injury-
induced PNP is associated with inflammatory reaction
and activation of glial cells in the corresponding spinal
cord segments [1, 3, 4].
Experimental PNP models are predominantly based on
injury to the sciatic nerve, wherein the maximum num-
ber of neuronal perikarya (98–99 %) is localized at the
L4 and L5 segments [5]. Sterile chronic constriction in-
jury (sCCI) of the sciatic nerve is a model for study of
cellular and molecular changes inducing PNP after trau-
matic nerve injury with dominant molecular signaling
from Wallerian degeneration [6]. It is well documented
that hypersensitivity and ongoing pain due to peripheral
nerve injury are associated with cellular and molecular
changes in the dorsal horn (DH) of the spinal cord re-
lated to activation of microglial cells and astrocytes and
alteration of pro- and anti-inflammatory cytokines pro-
duced by neurons, activated glia, and invaded immune
cells [7–12]. There is a growing body of evidence that
unilateral nerve injury results in bilateral neuroinflam-
matory reaction in the dorsal root ganglia and spinal
cord DH [10, 13–15], thus illustrating signaling from the
site of Wallerian degeneration to other compartments of
the nervous system [16].
CD200 is a membrane glycoprotein of the immuno-
globulin superfamily with immune suppression effect via
its receptor CD200R. CD200 has an extracellular portion
with two immunoglobulin domains, typical of proteins
involved in cell-to-cell interaction. The CD200 receptor
CD200R1 has a similar structure but with an additional
intracellular domain that is susceptible to phosphorylation
and involved in signal transduction [17, 18]. CD200 is
highly expressed on neurons while CD200R is confined
mainly to myeloid cells like macrophages and microglia
[19–23]. In addition, CD200 is expressed in oligodendro-
cytes [23] and astrocytes [23, 24]. The interaction of
CD200 with its receptor CD200R plays a significant role
in maintaining microglia in a quiescent or resting state
and attenuates various types of neuroinflammatory dis-
eases [19, 25, 26]. It has been demonstrated that mice with
levels of CD200 increased by spontaneous mutation in the
Wld gene have less activated monocytes and increasing
expression of IL-10 in the central nervous system follow-
ing induction of experimental autoimmune encephalomy-
elitis [27]. Conversely, CD200−/− mice have been shown
to display myeloid cell dysregulation, enhanced suscepti-
bility to experimental autoimmune encephalomyelitis [28],
and microglial activation [29]. Furthermore, CD200R ex-
pression can be modulated by IL-4 and IL-13 [30, 31].
Experimental studies have demonstrated that soluble
CD200 fusion protein (CD200Fc), containing the ecto-
domain of CD200 bound to a murine IgG2a module, at-
tenuates inflammatory diseases and reduces microglial
activation [32–36]. Nevertheless, our knowledge remains
limited as to the effects of CD200Fc in attenuation of glial
cell activation and alteration of pro- and anti-inflammatory
cytokines in PNP induced by a peripheral nerve injury.
Therefore, the goal of our present study was to explore
whether intrathecal application of CD200Fc might attenu-
ate activation of glial cells in the spinal cord, modify syn-
thesis of pro- and anti-inflammatory cytokines, and reduce
behavioral signs of PNP in the sCCI model. Our results
provide the first evidence that CD200Fc administration
induces rapid attenuation of glial activation and pro-
inflammatory cytokine synthesis of the spinal cord in
relation to reduction of neuropathic pain signs after
experimental nerve injury.
Methods
Animals and surgical procedures
The experiments were carried out on 120 male Wistar
rats weighing 240–250 g at the beginning of experiments.
The animals were housed on 12 h light/dark cycles at
temperature 22–24 °C under specific pathogen-free condi-
tions in the animal housing facility of Masaryk University.
All surgical procedures were performed by one person
under aseptic conditions and deep anesthesia induced by
a xylazine and ketamine cocktail injected intraperitoneally
(xylazine 1.6 mg/kg; ketamine 64 mg/kg). Sterilized food
and water were available ad libitum. Treatment of the
animals was in accordance with the European Conven-
tion for the Protection of Vertebrate Animals Used for
Experimental and Other Scientific Purposes and was
supervised by the institutional Ethics Committee of
Masaryk University in Brno (Czech Republic).
Six naïve rats treated with CD200Fc were used to
demonstrate that the CD200R agonist has no effect on
basal skin sensitivity, and 18 naïve rats were utilized for
comparison of glial activation by immunohistochemistry,
western blot analysis, and relative cytokine messenger
RNA (mRNA) levels. The left sciatic nerve was exposed
at mid-thigh and three silk ligatures (Ethicon 3–0) were
applied to reduce the nerve diameter by one third in the
rats undergoing sCCI (n = 72). The left sciatic nerves of
24 sham-operated rats were only exposed without any
nerve lesion. Sham- and sCCI-operated animals were left
to survive for 7 days.
Administration of CD200Fc and vehicle
At day 7 of sCCI operation, the rats were randomly
divided into groups with intrathecal administration of
CD200Fc for 5 h (n = 18; sCCI + CD200Fc5h) and 24 h
(n = 18; sCCI + CD200Fc24h) as well as a control group
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with intrathecal application of artificial cerebrospinal
fluid (ACSF) for 5 h (n = 18; sCCI + ACSF5h) and 24 h
(n = 18; sCCI + ACSF24h). CD200Fc (Cat. No. 3355-CD;
R&D Systems, Minneapolis, MN, USA) was freshly pre-
pared in sterile ACSF [37]. The single intrathecal injection
was administered by introducing a hypodermic needle
into the subarachnoid space of the cisterna magna for dif-
fusion of CD200Fc (5 μl; 2 μg/μl) or sterile ACSF (5 μl)
throughout the spinal fluid over 30 s with another 30-s
delay before removing the needle. To explore the effect of
surgical approach on inflammatory reaction in the spinal
cord, sham-operated rats were treated with ACSF (5 μl)
for 5 h (n = 18) and 24 h (n = 6, only for behavioral test). A
direct effect of CD200Fc on basal sensitivity was tested in
six naïve rats treated with CD200Fc (5 μl; 2 μg/μl) for 5
and 24 h.
Behavioral tests
Withdrawal thresholds for mechanical and thermal
hypersensitivity were measured in ipsilateral hind paws
using a dynamic plantar esthesiometer and plantar test
(Ugo Basile), respectively. Rats were first acclimated in
clear Plexiglas boxes for 30 min prior to testing. The
paws were tested alternately with 5-min intervals be-
tween tests 1 day before operation; 1, 3, and 7 days after
sCCI operation; and then 5 and 24 h after intrathecal
ACSF or CD200Fc treatment. Six naïve rats were tested
at 5 and 24 h after intrathecal administration to investi-
gate a possible CD200Fc effect on basal sensitivity of an-
imals. Five measurements were taken for each paw and
test session. In the case of thermal hypersensitivity, with-
drawal time was measured and the intensity radiance
was set at value 50. Data for mechanical and thermal
hypersensitivity were expressed as mean ± SE of with-
drawal thresholds in grams and withdrawal latency in
seconds, respectively. All behavioral tests were conducted
in a blind manner.
Immunohistochemical staining
The naïve rats and sCCI-operated rats treated with ACSF
or CD200Fc for 5 and 24 h, as well as sham-operated and
ACSF-treated rats (n = 6 for each group) were deeply
anesthetized with a lethal dose of sodium pentobarbital
(70 mg/kg body weight, i.p.) and perfused transcar-
dially with 500 ml of heparinized (1000 units/500 ml)
phosphate-buffered saline (PBS; 10 mM sodium phos-
phate buffer, pH 7.4, containing 0.15 M NaCl) followed
by 500 ml of Zamboni’s fixative [38]. The L4–L5 spinal
cord segments were removed, immersed separately in
Zamboni’s fixative at 4 °C overnight, and then collected
for each experimental group. The samples were washed in
20 % phosphate-buffered sucrose for 12 h and blocked in
Tissue-Tek® OCT compound (Miles, Elkhart, Ind.).
Serial transverse sections (12 μm) of the L4–L5 spinal
cord segments were cut (Leica 1800 cryostat; Leica
Microsystems, Wetzlar, Germany), collected on gelatin-
coated microscopic slides, air-dried, then processed for
immunohistochemical staining.
Briefly, the sections were washed with PBS containing
0.05 % Tween 20 (PBS-TW20) and 1 % bovine serum
albumin for 10 min, then treated with 3 % normal don-
key serum in PBS-TW20 for 30 min. The spinal cord
sections were incubated with 25 μl of mouse monoclonal
anti-CD11b/c antibody (OX42, 1:50; AbD Serotec,
Kidlington, UK) or rabbit polyclonal anti-glial fibrillary
acidic protein (GFAP, 1:250; Dako, Glostrup, Denmark)
in a humid chamber at room temperature (21–23 °C)
overnight or for 180 min to identify activated microglial
cells and astrocytes, respectively. The immunoreaction
was visualized by treatment with FITC-conjugated
affinity purified donkey anti-mouse or anti-rabbit sec-
ondary antibodies (1:400; Merck Millipore) for 90 min
at room temperature. A part of sections was incubated
overnight with mouse monoclonal anti-CD200 antibody
(OX2, 1:100; Abcam) and treated with FITC-conjugated
donkey anti-mouse (1:400; Merck Millipore) secondary
antibody. Spinal cord distribution of CD200R was de-
tected by immunostaining of sections with goat polyclonal
anti-CD200R (OX2R, 1:200; Santa Cruz Biotechnology,
Inc. USA) antibody and biotinylated donkey anti-goat
secondary antibody (1:400; Santa Cruz Biotechnology,
Inc. USA). Immunoreaction was visualized by TRITC-
conjugated streptavidin (1:100; Jackson Laboratories,
Inc. USA). The control sections were incubated with
omission of the primary antibodies (data not shown). The
cell nuclei were stained using Hoechst 33342 (Sigma; St.
Louis, MO, USA). Sections were mounted in Vecta-
shield aqueous mounting medium (Vector Laboratories;
Burlingame, CA, USA) and then observed and analyzed
using a Leica DMLB epifluorescence microscope equipped
with a Leica DFC-480 camera (Leica Microsystems
GmbH, Wetzlar, Germany).
Double immunofluorescence staining
To detect cellular localization of CD200 and CD200R
proteins in the spinal cord, simultaneous immunostaining
of CD200 or CD200R with corresponding cellular markers
was carried out. Activated astrocytes and microglial cells
were identified by immunostaining for GFAP and OX42,
respectively (see above). Immunofluorescence staining
with rabbit polyclonal NeuN antibody (1:500; Merck
Millipore) was used to identify neurons of the spinal
DH. Briefly, the spinal cord sections were immuno-
stained for CD200 (see above), and after washing, the
sections were immunolabeled with rabbit polyclonal
anti-GFAP or NeuN antibody and TRITC-conjugated
donkey anti-rabbit (1:400; Merck Millipore) secondary
antibody. Other sections were incubated at first to
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visualize distribution of CD200R and then for detection of
activated microglial cells using mouse monoclonal OX42
antibody and FITC-conjugated donkey anti-mouse sec-
ondary antibody (see above). The control sections of the
double immunostaining were incubated as described
above but with omission of CD200 or CD200R antibodies.
In the controls, no immunostaining for CD200 or CD200R
was detected in the spinal cord sections.
To detect CD200R in activated astrocytes, the sections
immunostained for CD200R using goat polyclonal anti-
body and biotin-streptavidin TRITC were next immuno-
labeled with rabbit anti-GFAP polyclonal antibody and
FITC-conjugated donkey anti-rabbit secondary antibody
(see above). The control sections were incubated with
the goat anti-CD200R polyclonal antibody and FITC-
conjugated donkey anti-rabbit secondary antibody or
with rabbit anti-GFAP polyclonal antibody, and next, a
biotin-streptavidin procedure was used for visualization
of CD200R. No cross reaction between the secondary
and primary antibodies was detected in these control
sections. Double immunostained sections were mounted
in Vectashield aqueous mounting medium and analyzed
using a Nikon Eclipse epifluorescence microscope equipped
with a DS-Ri1 camera (NIKON, Czech Republic).
Because detection of CD200R expression in acti-
vated astrocytes is not routine, the colocalization of
CD200R and GFAP immunofluorescence was analyzed
by colocalization module of NIS Elements software
(Nikon, Czech Republic).
Image analysis
At least 10 sections (each separated from the next by an
interval of about 80 μm) from each of the removed L4–
L5 spinal cord segments for each animal per experimen-
tal group were selected for image analysis. Immunostain-
ing area for OX42 or GFAP in spinal cord sections was
measured using an NIS elements image analysis system
(Laboratory Imaging Ltd, Prague, Czech Republic).
Briefly, a box (4 × 104 μm2) was placed over the lateral,
central, and medial areas of DH and OX42 or GFAP
immunostained structures were detected by threshold-
ing technique after subtraction of background. The area
of immunostaining for OX42 or GFAP in correspond-
ing DH was related to the area of interest (4 × 104 μm2)
and expressed as the mean of relative area (%) ± SD.
Western blot analysis
Rats were deeply anesthetized with a lethal dose of so-
dium pentobarbital (70 mg/kg body weight, i.p.). The
L4–L5 spinal cord segments were detected following
total laminectomy and rapidly removed, frozen in dry
ice, then stored at −70 °C until elaboration for western
blot or reverse transcription (RT) and real-time polymer-
ase chain reaction (PCR).
The fresh tissue samples of L4–L5 spinal cord seg-
ments from six animals for each group were homoge-
nized in PBS containing 0.1 % Triton X-100 and
protease inhibitors (LaRoche, Switzerland) and then
centrifuged at 10,000g for 5 min at 4 °C. Proteins were
separated by SDS-polyacrylamide gel electrophoresis
[39] and transferred to nitrocellulose membranes by
electroblotting (Bio-Rad). Blots were blocked by 5 %
milk-TBST for 1 h and incubated with mouse monoclonal
OX42 antibody (1:300; AbD Serotec), rabbit polyclonal
anti-GFAP (1:250; DAKO), goat polyclonal anti-CD200
(1:100; Santa Cruz Biotechnology), or anti-CD200R anti-
body (1:100; Santa Cruz Biotechnology) at 4 °C for 18 h.
Blots were washed in PBS-TW20 and incubated with
secondary antibody (goat anti-mouse or anti-rabbit, 1:1000,
Immunotech; anti-goat, 1:8000, Bio-Rad), at room
temperature for 1 h. Protein bands were visualized using
the ECL detection kit (Amersham) on an LAS-3000 chemi-
luminometer reader (Bouchet Biotech) and analyzed using
densitometry image software. The blots were stripped in
62.5 mM Tris–HCl, pH 6.8, containing 2 % SDS and 0.7 %
β-mercaptoethanol, and they were then reprobed with a
monoclonal antibody against β-tubulin (1:5000; Exbio).
Reverse transcription and real-time polymerase chain
reaction
The fresh tissue samples of L4–L5 spinal cord segments
from six animals for each group were collected. Total
RNA was extracted using RNeasy mini columns (Qiagen,
Hilden, Germany). Contaminating genomic DNA was
degraded by a treatment with DnaseI (Qiagen). The
yield of RNA was determined using a Nanodrop® spec-
trophotometer (NanoDrop Technologies, Wilmington,
DE, USA). Total RNA (1 μg in 20 μL) was reverse tran-
scribed into complementary DNA (cDNA) using poly-dT
primers and the Promega reverse transcription kit
(Promega, Madrid, Spain). The oligonucleotide primer
sequences used are given in Table 1. SYBR® PCR was
performed using 1 μL of cDNA (corresponding to
50 ng RNA input) with 200 nM of the primers listed
above (Invitrogen, Barcelona, Spain) in a Power SYBR®
PCR Mastermix (Applied Biosystems, Foster City, CA,
USA). Cycling conditions were as follows: 50 °C for 2 min,
95 °C for 10 min, and 40 amplification cycles of 95 °C for
15 s and 60 °C for 1 min. Samples were assayed using the
Applied Biosystems PRISM 7500 sequence detection
system, assaying each sample in triplicate and running a
six-point standard curve in parallel. To ensure the absence
of contamination with genomic DNA, a control sample
using RNA as the template was run for each set of extrac-
tions. Relative quantification was obtained by calculating
the ratio between the values obtained for each gene of
interest and those of the 18S housekeeping gene with re-
spect to the naïve animals.
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Statistical analyses
Behavioral data were evaluated using Kruskal-Wallis
one-way analysis with Bonferroni post hoc test and p
values less than 0.05 were considered to be significant.
To verify differences of immunostaining area, western
blot and RT-PCR, a one-way ANOVA with subsequent
post hoc t tests employing a correction of alpha according
to Bonferroni for repeated measures was run with p < 0.05
as the level of significant differences between tested
samples. Statistical differences between data of relative
immunostaining area, western blot, and RT-PCR were
tested by Mann-Whitney U test (p < 0.05). All statistical
analyses were made using STATISTICA-12 software
(StatSoft, Tulsa, OK, USA).
Results
CD200Fc reduces mechanical and thermal
hypersensitivity of nerve-injured rats
As CD200Fc appears to be beneficial when administered
in cases of various diseases with an inflammatory compo-
nent [34, 36, 40], we investigated whether the CD200R1
agonist has effects on PNP behavioral signs in the sCCI
model. No statistically significant changes of thresholds
and withdrawal latencies were measured in the hind paws
of naïve rats treated with CD200Fc for 5 and 24 h, thus
indicating no influence of the CD200R agonist on basal
sensitivity (data not shown). Sham-operated rats displayed
a small but not statistically significant mechanical and
thermal hypersensitivity at days 1 and 3 with no behavioral
changes after 7 days and ACSF treatment for 5 or 24 h
(Fig. 1a, b). All hind paws of rats subjected to sCCI of the
sciatic nerve displayed significantly decreased thresholds of
mechanical (Fig. 1a) and withdrawal latencies of thermal
hypersensitivity (Fig. 1b) at days 1, 3, and 7 post-operation
when compared with 1 day before operation.
Rats operated on sCCI with intrathecal administration
of CD200Fc for 5 h displayed significant attenuation of
mechanical and thermal hypersensitivity when compared
with levels before CD200Fc injection or with ACSF-
treated rats. Thresholds of mechanical and withdrawal
latencies of thermal hypersensitivity did drop 24 h after
CD200Fc administration, but the values remained still
significantly higher when compared with levels before
CD200Fc treatment (Fig. 1a, b).
CD200Fc attenuates activation of microglial cells and
astrocytes in the spinal dorsal horn of nerve-injured rats
We investigated the regulatory effect of CD200Fc ad-
ministration on microglial activation in the sCCI model
of PNP because interaction of CD200 with CD200R de-
creases microglial activation [20, 33]. No significant dif-
ference of OX42 immunostaining was found between
naïve and sham-operated rats (Fig. 2a, d, h). The OX42
immunoreactive area indicating activated microglial cells
was markedly larger in ipsilateral DH of the spinal cord
sections from sCCI-operated and ACSF-treated rats
when compared with naïve or sham-operated animals
(Fig. 2b, e). Microglial activation expressed by the OX42
immunoreactive area was significantly attenuated in ipsi-
lateral DH sections prepared from the spinal cord of
sCCI-operated rats and treated with CD200Fc for 5 h
(Fig. 2c, f ). However, 24 h after CD200Fc injection, the
OX42 immunostaining area was enlarged, but it
remained smaller than in control group of sCCI-
operated and ACSF-treated rats (Fig. 2g). In contrast to
ipsilateral DH, no significant extension of OX42 immu-
noreactive area was detected in the contralateral DH of
sCCI-operated rats treated with ACSF or CD200Fc in
comparison to naïve or sham-operated rats (Fig. 2i–k).
The microglial cells immunostained for OX42 displayed
the typical activated, amoeboid morphology in sections
of L4–L5 spinal cord segments from rats sCCI-operated
and treated with ACSF, whereas those in sections from
CD200Fc-treated rats exhibited a ramified morphology
similar to microglia of the naïve animals (insets in
Fig. 2d–f ). Quantitative changes of microglial activation
detected by OX42 immunostaining area in the spinal
cord sections of naïve, sham- and sCCI-operated, and
ACSF- or CD200Fc-treated rats (Fig. 2l) were confirmed
by western blot analysis of CD11b/c protein (Fig. 2m).
As CD200Fc appears to attenuate microglial activation
in the sCCI-operated rats, we investigated whether intra-
thecal application of CD200Fc would also affect astro-
glial activation. Lumbar spinal cord sections prepared
from rats 7 days after sCCI operation and treatment
with ACSF displayed a bilateral enlargement of GFAP
immunostaining area in DH when compared to the
spinal cord sections of naïve or sham-operated rats
(Fig. 3a–b, d–e, h–i). In comparison to ACSF treatment,
Table 1 Rat primer sequences used in quantitative polymerase chain reactions
Genes Forward Reverse
IL-1β 5′-TTGCTTCCAAGCCCTTGACT-3′ 5′-CTCCACGGGCAAGACATAGG-3′
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intrathecal administration of CD200Fc bilaterally reduced
the extent of astroglial GFAP immunostaining in L4–L5
spinal cord sections from sCCI-operated rats (Fig. 3c, f, j).
The GFAP-immunostained area of activated astrocytes
was enlarged at 24 h after CD200Fc treatment, but it still
remained lower than in the spinal cord of sCCI-operated
and ACSF-treated rats. The quantitative changes of
GFAP-immunoreactive areas (Fig. 3l) indicating activation
state of astrocytes were confirmed by western blot analysis
of GFAP protein in the spinal cord of naïve, sham-
operated, and sCCI-operated and treated rats (Fig. 3m).
Cellular distribution and regulation of CD200 and
CD200R1 levels in the spinal cord of nerve-injured and
CD200Fc-treated rats
To determine precisely whether exogenous soluble
CD200Fc might modify membrane-bound CD200 and
CD200R1 expression in the spinal cord after sCCI
operation, we analyzed their proteins by immuno-
fluorescence staining and western blotting in naïve
and sham-operated rats in comparison with those of
sCCI-operated animals after ACSF and CD200Fc ad-
ministration for 5 h. The CD200 immunostaining was
dominantly observed in DH with a higher intensity in
the spinal cord sections from sCCI-operated and
ACSF-treated rats when compared with that from
sham-operated or sCCI-operated and CD200Fc-treated
rats (Fig. 4a–c). Similarly, a distinctly increased immuno-
staining for CD200R1 was found in DH of spinal cord
sections of sCCI-operated and ACSF-treated rats when
compared with sections of the spinal cord from sham-
operated rats (Fig. 4d–f ). The increased CD200 and
CD200R1 proteins in the spinal cord of sCCI-operated
and ACSF-treated as well as the protein decrease after
CD200Fc injection were confirmed by western blot
analysis (Fig. 4g, h).
Fig. 1 Results of behavioral tests. Mechanical (a) and thermal hypersensitivity (b) in sCCI-operated rats treated with ACSF or CD200Fc. Withdrawal
thresholds for mechanical hypersensitivity and latencies for thermal hypersensitivity were significantly decreased in the ipsilateral hind paws
following sCCI when compared with 1 day before surgery, and CD200Fc treatment for 5 h was able to reverse these. Both behavioral signs of
PNP were nevertheless significantly weaker 24 h from CD200Fc application, although they remained still higher than 7 days after sCCI operation but before
CD200Fc application. All values in a and b represent mean ± SE from six rats per group. Asterisk indicates statistically significant difference (p< 0.001) when
compared with measurements 1 day before operation; Plus sign indicates statistical significant difference (p < 0.01) when compared to values
of sCCI-operated animals before and after CD200Fc application. Kruskal-Wallis ANOVA followed by Mann-Whitney U test.
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Double immunostaining of spinal cord sections of sCCI-
operated and ACSF-treated rats revealed CD200 immuno-
reaction in both NeuN+ neurons and GFAP+ astrocytes
(Fig. 5a–f ). The CD200R immunofluorescence was de-
tected in neuropil of the spinal cord sections and double
immunostaining displayed colocalization of CD200R and
OX42 to illustrate presence of CD200R in activated
microglial cells (Fig. 5g–i). When GFAP immunostaining
corresponding with astrocyte activation was reduced after
CD200Fc treatment, we sought to observe whether acti-
vated astrocytes could express CD200R1. Surprisingly,
CD200R immunolabeling was colocalized with GFAP
Fig. 2 Immunofluorescence staining and quantification of CD11b/c protein. OX42 (CD11b/c protein) immunofluorescence to detect microglia in
the dorsal horn (DH) of sections through L4–L5 spinal cord segments from naïve and sham-operated rats as well as sCCI-operated rats treated
with ACSF or CD200Fc. Representative pictures of OX42 immunofluorescence in ipsilateral DH of the spinal cord from sham- (a) and CCI-operated
(b, c) rats 5 h after ACSF (a, b) or CD200Fc (c) injection. Scale bars = 75 μm. A higher power magnification of OX42 immunofluorescence in DH of
naïve (d) and sham-operated (h) rats and the ipsi- and contralateral DH (DH-ipsi, DH-contra) of sCCI-operated and ACSF-treated rats (e, i) as well
as 5 (f, j) or 24 h (g, k) after injection with CD200Fc. Scale bars = 50 μm. Insets in d–f show typical shape of OX42-labeled microglia in DH of naïve,
ACSF-, and CD200Fc-treated rats, respectively. Scale bars for insets = 33 μm. l Bar graph shows quantification of OX42 immunostaining area in DH
of L4–L5 spinal cord segments from naïve and sham-operated rats as well as sCCI-operated rats for 7 days and 5 or 24 h after administration of
CD200Fc or ACSF. m Western blot shows increased CD11b/c protein level in the spinal cord of sCCI-operated in comparison to naïve or sham-
operated rats, whereas CD200Fc administration reduced this elevation. The data represent the mean ± SD optical density normalized to tubulin
from six animals in each group. *p < 0.05 when compared to DH of naïve or sham-operated rats; #p < 0.05 when compared to DH of sCCI + ACSF
rats; ++p < 0.05 when compared to 5-h treatment. Mann-Whitney U test
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immunostaining, indicating expression of the receptor in
activated astrocytes of the spinal cord from sCCI-operated
rats (Fig. 6a–f ). The unexpected colocalization was
verified by image analysis and measurement of indexes
using NIS Elements. Mander’s overlap measured in double
immunostained cells indicated by arrows (Fig. 6d–f ) was
0.965265, 0.929336, and 0.960253. In addition, profile in-
tensity of red (CD200R) and green (GFAP) channels in the
cells also indicated colocalization of CD200R and GFAP
immunostaining (Fig. 6g).
Intrathecal CD200Fc administration reduces
proinflammatory and enhances anti- inflammatory cytokine
mRNAs in lumbar spinal cord segments of nerve-injured rats
To determine the immediate effect of CD200Fc treat-
ment on cytokine synthesis in the spinal cord 7 days
Fig. 3 Immunofluorescence staining and quantification of GFAP protein. GFAP-immunoreactive astrocytes in the dorsal horn (DH) of sections
through L4–L5 spinal cord segments from naïve rats and sham-operated rats as well as sCCI-operated rats treated with ACSF or CD200Fc.
Representative pictures of GFAP immunostaining in ipsilateral (ipsi) and contralateral (contra) DH of the spinal cord from sham- (a) and
CCI-operated (b, c) rats 5 h after ACSF (a, b) or CD200Fc (c) injection. Scale bars = 100 μm. A higher power magnification of GFAP immunostaining in
DH of naïve (d) and sham-operated (h) rats and the ipsi- and contralateral DH (DH-ipsi, DH-contra) of sCCI-operated and ACSF-treated rats (e, i) as well
as rats 5 (f, j) or 24 h (g, k) after injection with CD200Fc. Scale bars = 50 μm. l Bar graph shows quantification of GFAP-immunoreactive area in DH of
L4–L5 spinal cord segments from naïve and sham-operated rats as well as sCCI-operated rats for 7 days and 5 or 24 h after administration of CD200Fc
or ACSF. m Western blot confirmed the increase of GFAP protein level in the spinal cord of sCCI-operated in comparison to naïve or sham-operated
rats. The GFAP elevation was reduced by CD200Fc administration. The data represent the mean ± SE optical density normalized to tubulin from six
animals in each group. *p < 0.05 when compared to DH of naïve or sham-operated rats; #p < 0.05 when compared to DH of sCCI + ACSF rats.
Mann-Whitney U test
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after sCCI operation, RT-PCR was carried out using
primers specific to pro- (TNF, IL-1β, IL-6) and anti-
inflammatory (IL-4, IL-10) cytokines.
As expected, L4–L5 segments of the spinal cord from
sCCI-operated and ACSF-treated rats displayed robust
elevation of relative mRNAs of proinflammatory (TNF,
IL-1β, IL-6) and a decrease of anti-inflammatory cytokines
(IL-4, IL-10) when compared with spinal cord segments of
naïve or sham-operated rats. After 5 h, intrathecal admin-
istration of CD200Fc produced normalization of TNF
mRNA expression (Fig. 7a) and significant reduction in
relative expression of IL-1β and IL-6 mRNAs (Fig. 7b–c)
in comparison with ACSF-treated rats. Conversely, rela-
tive levels of IL-4 and IL-10 mRNAs were simultaneously
increased close to (in the case of IL-4) or exceeding (for
IL-10) those levels for spinal cord segments from naïve or
sham-operated rats (Fig. 7d–e).
Discussion
Many experimental models of PNP are principally based
on peripheral nerve injury providing a partial disconnec-
tion of axons from their neuronal bodies [6, 41]. The
original model of CCI using four ligatures of chromic
gut (4–0) loosely tied around the sciatic nerve [42] is
not suitable for distinguishing neuroinflammatory reac-
tion induced by a thread material [43] and/or Wallerian
degeneration of injured axons [6]. Therefore, sCCI of
the sciatic nerve in our experiments was prepared using
Fig. 4 Effect of CD200Fc on CD200 and CD200R1 protein levels. Effect of CD200Fc on CD200 and CD200R1 protein levels of the L4–L5 spinal
cord segments from sCCI-operated rats. sCCI of the sciatic nerve and ACSF treatment increased intensity of CD200 and CD200R immunofluorescences
in DH of spinal cord sections when compared with those from sham-operated rats. Intrathecal CD200Fc administration significantly attenuated
elevation of CD200 and CD200R immunofluorescences in the spinal cord sections of sCCI-operated rats (a–f). Scale bars = 100 μm. The
CD200 and CD200R immunofluorescence changes were confirmed by western blot analysis of CD200 and CD200R proteins (g, h). Upper
panels of g and h illustrate representative western blotting bands for CD200 and CD200R in the L4–L5 spinal cord segments from sham-operated
(Sham), sCCI-operated and ACSF-treated (sCCI + ACSF5h) rats, as well as rats operated for sCCI and 5 (sCCI + CD200Fc5h) or 24 h (sCCI + CD200Fc24h)
after administration of CD200Fc. Lower panels show mean density ± SE of individual CD200 and CD200R1 protein bands in triplicate analysis of six animals
after normalization to tubulin. *p< 0.05 when compared to naïve rats; #p < 0.05 when compared to sCCI + ACSF rats; ++p< 0.05 when compared to 5 h
after administration of CD200Fc. Mann-Whitney U test
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3–0 sterilized thread (Ethicon) under aseptic conditions
to study the effect of CD200Fc on spinal glial activation
and cytokine reactions in consequent Wallerian de-
generation induced by traumatic nerve compression.
It is well known that PNP induced by nerve injury is
related to activation of glial cells and upregulation of
proinflammatory cytokines in the spinal cord, and
their reduction has been associated with alleviation of
behavioral signs [44–47].
CD200/CD200R is a regulatory system of inflamma-
tion that plays a relevant role in various diseases
when CD200 ligand binding with its receptor is im-
paired [22, 25, 29]. In contrast, enhanced signaling of
CD200R by CD200Fc treatment alleviates pathological
effects of inflammation [32, 34–36]. However, the
anti-neuroinflammatory effects of CD200Fc in neuro-
pathic pain have not heretofore been investigated. The
present study provides the first evidence that CD200Fc
attenuates activation of glial cells and proinflammatory
cytokines, as well as mechanical and thermal hypersensi-
tivity in an experimental model of PNP immediately after
its intrathecal administration.
CD200Fc has been applied intraperitoneally [35], sub-
cutaneously [34], or intracerebroventricularly [32] in
various experimental models of inflammatory diseases.
As CD200Fc has a half life of just a few hours [48], we
applied the CD200R soluble ligand intrathecally to
achieve direct and rapid diffusion of CD200Fc into DH
of the rat spinal cord. We cannot exclude the possibility
that a small portion of the drug administered into the
cisterna magna will retrogradely reach the ventricular
system and surrounding structures playing a role in the
effects described here. However, decreased glial activa-
tion and modulation of cytokine mRNAs and CD200/
CD200R changes revealed that CD200Fc diffused into
the lumbar level of spinal cord.
CD200Fc attenuates glial activation of the spinal cord and
neuropathic pain behavioral signs
Activation of microglial cells and astrocytes after nerve
injury is strongly associated with induction and mainten-
ance of mechanical and thermal hypersensitivity, and de-
pression of the glial activities alleviates the behavioral
signs of PNP [46, 49–51]. Microglial cells are accumu-
lated in the spinal cord at the ipsilateral side to nerve in-
jury and change their morphology from a “resting state”
in which the cell bodies are small with long and thin
processes into an “activated state” in which the cells
present an amoeboid shape with their bodies enlarged
and fine processes retracted [52, 53]. Microglial activa-
tion after peripheral nerve injury is generally detected by
immunocytochemical staining using the OX42 antibody,
Fig. 5 Double immunostaining to detect CD200 protein in astrocytes and neurons as well as CD200R in microglia. Double immunostaining of
sections through DH of L4–L5 spinal cord segments from sCCI-operated and ACSF-treated rats. Immunofluorescence for CD200 (a) and GFAP (b)
are colocalized (c), evidencing that CD200 protein is expressed by astrocytes (arrows). In addition, double immunostaining for CD200 (d) and
NeuN (e) detected a presence of CD200 protein also in neurons (f, arrows). Immunolabeling for CD200R (g) and OX42 (h) was colocalized,
illustrating that activated microglial cells display CD200R protein (i, arrow). Merged figures (c, f, i) contain also blue channel of Hoechst
stained nuclei. Scale bars = 30 μm
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directed against a complement receptor 3 antigen
(CD11b/c) or antibody against ionized calcium binding
adapter molecule 1 (Iba1) [54, 55]. However, there is
convincing evidence that enlarged OX42 immunostain-
ing area measured by image analysis is related with
microglial activation after nerve injury [53].
Ipsilateral DH of the spinal cord from sCCI + ACSF in
contrast to naïve or sham-operated rats displayed enlarged
areas of OX42 immunofluorescence and appearance of
OX42+ microglial cells with the shapes indicating their ac-
tivated state. The OX42 immunoreaction area was signifi-
cantly reduced in DH of sCCI-operated and CD200Fc-
treated rats, thus showing very rapid effect on the marker
of activated microglia. The changes of microglial cell
activation induced by CD200Fc were confirmed by
western blot analysis of the CD11b/c protein. Our results
are in agreement with other experimental studies in
that CD200Fc rapidly reduced the markers of microglial
activation [32, 34, 56].
Astrocytes are more dominant than microglia in the
spinal cord, and they have been investigated predomin-
antly in relation to their supportive functions for neu-
rons [57]. Moreover, activated astrocytes are a major
source of cytokines and may contribute significantly to
induction and maintenance of PNP [45, 49]. Astrocytes
respond to various physiological or pathological stimuli
with the increased expression of GFAP that is generally
considered to be a marker for astrocyte activation [58].
It has been experimentally demonstrated that GFAP up-
regulation in the spinal cord correlates well with nerve
injury-induced PNP [49] and that suppression of astro-
cyte activation by fluorocitrate alleviates PNP symptoms
[59]. In our experiments, as demonstrated by GFAP im-
munofluorescence areas and western blot analysis of
GFAP protein, astrocytes became activated in sCCI-
operated and ACSF-treated rats and were reduced bilat-
erally in DH of the spinal cord after treatment with
CD200Fc. This suppression of activated astrocytes was
much less than microglial cells which is in accordance
with treatment by selective inhibitors of glial activation
[55]. Our results of western blot analysis were obtained
from whole L4–L5 segments containing possible changes
also in the ventral horn of the spinal cord. However,
OX42 and GFAP protein levels correlated with quantita-
tive alterations of corresponding immunofluorescence
were measured only in DH of the spinal cord.
Our present results evidence for the first time that
intrathecal application of CD200Fc for 5 h diminished
Fig. 6 Double immunostaining to detect CD200R protein in astrocytes. Double immunostaining of section through DH of L4–L5 spinal cord
segments from sCCI-operated and ACSF-treated rats to detect CD200R protein in GFAP positive astrocytes. Immunofluorescence staining for GFAP
(a, d) and CD200R (b, e) was colocalized as shown in merged figure (c, f). Scale bars = 100 μm. d–f illustrate a higher power magnification of area
limited by a box in c. Evidence of CD200R in activated astrocytes was confirmed by image analysis of three cells in the section using NIS Elements
software. Mander’s overlap was 0.965265, 0.929336, and 0.960253 for cells indicated by arrows. Scale bars = 30 μm. g illustrates representative
profile intensity of red (CD200R) and green (GFAP) channels in cell tagged 1
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activation of both microglia and astrocytes in DH of
the spinal cord after sciatic nerve injury. This rapid
but reversible suppression of microglia and astrocyte
activations runs in parallel with alleviation of both
mechanical and thermal hypersensitivity. Because both ac-
tivated microglial cells and astrocytes displayed CD200R,
its activation by CD200Fc explains attenuation of the glial
activation and consequent alleviation of nerve injury-
induced PNP like in experimental studies using other
modulators of glial activation [34, 46, 60]. Very rapid
suppression of activated glial cells by CD200Fc was
not surprising inasmuch as intrathecal injection of
other drugs has been shown to abolish glial activa-
tion within hours [46, 61]. The CD200Fc effect was
already weakened 24 h from single injection, how-
ever, thus indicating the necessity of repeated admin-
istration for longer PNP attenuation, as is usual for
other molecules modulating neuroinflammation or
pain [62, 63].
Expression of CD200 and CD200R in the dorsal horn of
spinal cord
CD200 protein is constitutively expressed in neurons
and to a lesser extent in reactive astrocytes while
CD200R is expressed by microglia [21, 23]. The changes
of CD200 and CD200R1 protein levels in the spinal cord
after nerve injury and following administration of
CD200Fc have not previously been described. The
CD200 and CD200R immunostaining was predomin-
antly found in the spinal dorsal horn and both immuno-
fluorescence staining and western blot analysis revealed
significantly higher levels of CD200 and CD200R pro-
teins in the spinal cord after sCCI of the sciatic nerve. In
contrast to neurodegenerative diseases [19, 25, 64],
sciatic nerve injury probably activated endogenous regu-
latory mechanisms including upregulation of CD200/
CD200R. Intrathecal CD200Fc treatment following sci-
atic nerve injury suppressed CD200 and CD200R pro-
teins in the spinal cord to levels close to those of naïve
Fig. 7 RT-PCR analysis of cytokine RNAs in the spinal cord after CD200Fc administration. Effect of CD200Fc on TNF, IL-1β, IL-6, IL-4, and IL-10
mRNAs expression in L4–L5 segments of spinal cord from sCCI-operated rats for 7 days. sCCI of the sciatic nerve and ACSF treatment increased
levels of TNF (a), IL-1β (b), and IL-6 (c) as well as decreased IL-4 (d) and IL-10 (e) mRNA expression in the lumbar spinal cord segments. Intrathecal
CD200Fc administration prevented the increase of TNF, IL-1β, and IL-6 as well as the decrease of IL-4 and IL-10 mRNAs expression in the lumbar
spinal cord segments. The mRNA expression of each gene (n = 6 per group) was normalized to that of the 18S gene and the data represent the
mean ± SD. *p < 0.05, **p < 0.001 when compared to naïve rats; +p < 0.05, ++p < 0.001 when compared to sham-operated rats; #p < 0.05 when
compared to sCCI + ACSF rats. Mann-Whitney U test
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or sham-operated rats. The rapid regulation of the
CD200 and CD200R proteins was parallel with activation
or deactivation of microglia cells and astrocytes detected
by CD11b/c or GFAP markers, respectively.
Using double immunostaining, we confirmed a presence
of CD200 protein in neurons and astrocytes as well as
CD200R in microglial cells as described earlier [21, 23].
However, there are no uncompromising results about ex-
pression of CD200R in astrocytes. We detected colocaliza-
tion of GFAP and CD200R immunostaining in the spinal
DH of sCCI-operated and ACSF-treated rats, thus indicat-
ing a presence of CD200R protein also in astrocytes acti-
vated by nerve injury. Activation of both microglia and
astrocytes might therefore be directly modulated by
CD200Fc through stimulation of CD200R. Intense cross
talk between glial cells in the spinal DH is induced in the
initiation phase of injury-induced PNP [8, 55, 65]. CD200/
CD200R-mediated suppression of neuroinflammation may
occur not only via neuron-microglia interactions but also
via glia-glia interactions [23]. In addition to neurons,
increased expression of CD200 in reactive astrocytes may
contribute to control of microglial activation, while
CD200R upregulation probably allows a modulation of
astrocyte activation by contact with CD200+ neurons.
CD200Fc decreases proinflammatory and increases
anti-inflammatory cytokine mRNAs in the spinal cord of
nerve-injured rats
In the present time, there is no evidence about direct
operation of CD200/CD200R dysbalance in neuropathic
pain induction. It is generally accepted that CD200/
CD200R modulatory system is involved in suppression of
inflammation and glial activation. Although the recruit-
ment of neutrophils, macrophages, and lymphocytes from
blood might participate in the neuroimmune response of
the spinal cord to nerve injury, the activation of microglia
and astrocytes undoubtedly plays a pivotal role in produc-
tion of cytokines and chemokines [10, 12, 54].
A nerve injury induces elevation of proinflammatory
cytokine levels and their synthesis (mRNA) in the spinal
cord associated with development and maintenance of
PNP [66–68]. Experimental studies have demonstrated
that suppression of proinflammatory cytokines like TNF,
IL-1β, and IL-6 is necessary for efficacious attenuation
of mechanical and thermal hypersensitivity [67, 69, 70].
In contrast, increased synthesis or delivery of IL-10 has
been shown to attenuate proinflammatory cytokine
levels and alleviated PNP [71]. Similarly, other anti-
inflammatory cytokines, such as IL-4, also have been de-
creased in the CCI model of PNP and IL-4 deficiency
has been associated with mechanical hypersensitivity
[72]. Accumulating evidence indicates that nerve injury
induces upregulation of pro- and anti-inflammatory cy-
tokines in activated microglia and astrocytes in relation
with development and maintenance of PNP [7, 10, 44].
Our results from RT-PCR showed increase of proinflam-
matory cytokine (TNF, IL-1β, IL-6) and decrease of anti-
inflammatory cytokine (IL-4, IL-10) mRNAs in the spinal
cord of nerve-injured rats in comparison with naïve and
sham-operated animals. Intrathecal CD200Fc treatment
diminished elevation of proinflammatory cytokine (TNF,
IL-1β, IL-6) mRNAs and simultaneously ameliorated def-
icit of IL-4 and IL-10 mRNAs induced by unilateral sCCI
of the sciatic nerve. This modulation of pro- and anti-
inflammatory cytokine mRNAs by CD200Fc treatment
was simultaneous with glia deactivation and attenuation
of mechanical and thermal hypersensitivity.
CD200R1 stimulation suggests that CD200/CD200R1
interaction is involved in suppression of the proinflamma-
tory phenotype of microglial cells [32–34, 73] and astro-
cytes. In addition, an in vitro study showed how microglia
incubation with CD200-bearing astrocytic membrane
preparations mitigates the LPS-induced increase in
mRNA expression of the proinflammatory cytokines TNF,
IL-1β, and IL-6 [74]. In line with our findings, CD200Fc
treatment significantly decreased the production of TNF
and IL-6 but not of IL-10 or TGF-β in microglial cells of
mice with experimental autoimmune encephalomyelitis
[34]. Referring to anti-inflammatory cytokines, it has been
pointed out that there is a possible involvement of
CD200Fc in increasing IL-4 and IL-10 in microglia cells
[33, 56]. Moreover, an increased expression of IL-10 in re-
lation to enhanced neuronal levels of CD200 has been also
found in the central nervous system of experimental auto-
immune encephalomyelitis mice [27].
The present results indicate that sciatic nerve injury-
induced upregulation of proinflammatory cytokines in
parallel with elevation of the CD200/CD200R regulatory
system. An enhanced signaling of CD200R1 by CD200Fc
treatment attenuated activation of microglial cells and
astrocytes simultaneously with a decrease of proinflam-
matory and increase of anti-inflammatory cytokine syn-
thesis. Due to reduction of the inflammatory reaction by
CD200Fc, expression of the CD200/CD200R regulatory
system was diminished.
In conclusion, our results suggest that support of the
CD200/CD200R regulatory system by administration of
the CD200R1 agonist CD200Fc induces very rapid sup-
pression of neuroinflammatory reactions associated with
glial activation and PNP development. This may consti-
tute a promising and novel therapeutic approach for the
treatment of PNP. Additional experiments with nerve
injury models are nevertheless needed, and particularly
with repeated CD200Fc treatment to prolong its effect.
Conclusions
The present results indicate that sCCI of the sciatic nerve
induced upregulation of proinflammatory cytokines in
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parallel with elevation of the CD200/CD200R regulatory
system. An enhanced signaling of CD200R1 by adminis-
tration of the CD200R1 agonist CD200Fc induces very
rapid suppression of glial activation in the spinal cord
simultaneously with a decrease of proinflammatory and
increase of anti-inflammatory cytokine synthesis associ-
ated with attenuation of PNP development. Due to reduc-
tion of the inflammatory reaction by CD200Fc, expression
of the CD200/CD200R regulatory system was diminished.
Support of the CD200/CD200R regulatory system
by administration of the CD200R1 agonist CD200Fc
may constitute a promising and novel therapeutic ap-
proach for the treatment of PNP. Additional experiments
with nerve injury models are nevertheless needed and
particularly with repeated CD200Fc treatment to prolong
its effect.
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